Table 1 Progress of patient between December 2014 and November 2022
Date | PRL (3.4–19.1 ug/L) | FT4 (9.0–19.0 pmol/L) | Total testosterone (4.9–32.0 nmol/L) | Tumor size (cm) | Medication |
|---|---|---|---|---|---|
December 2014 | > 470 | 10.7 | 5.16 | CC: 2.4 TR: 2.0 AP: 2.0 | CAB 0.5 mg 2×/week LT4 25 mcg OM |
June 2015 | 121.9 | – | – | CC: 1.3 TR: 1.5 AP: 1.8 | CAB 0.75 mg 2×/week LT4 75 mcg OM |
July 2016 | 24.1 | 13.0 | 4.6 | CC: 1.4 TR: 1.7 AP: 1.8 | CAB 0.75 mg 2×/week LT4 75 mcg OM |
December 2017 | > 197.4 | 12.0 | 2.2 | CC: 1.5 TR: 1.7 AP: 2.1 | CAB 0.75 mg 2×/week LT4 75 mcg EOD LT4 100 mcg EOD |
February 2020 | 93.8 | 10.5 | 1.4 | CC: 2.5 TR: 1.8 AP: 1.7 | CAB 0.75 mg 2×/week LT4 50 mcg M-F LT4 25 mcg S,S T 100 mg q28 days |
February 2021 | 160.8 | – | – | CC: 2.2 TR: 1.6 AP: 1.7 | CAB 0.75 mg 2×/week LT4 25 mcg M-T LT4 50 mcg F-S T 100 mg q28 days |
December 2021 | 271.1 | 10.2 | - | CC: 2.8 TR: 2.0 AP: 1.9 | CAB 1.5 mg, 1.5 mg, 1 mg LT4 25 mcg M-T LT4 50 mcg F-S T 100 mg q28 days |
April 2022 | 280.8 | - | - | CC: 2.9 TR: 1.9 AP: 1.6 | CAB 1.5 mg 3×/week LT4 25 mcg M-T LT4 50 mcg F-S T 100 mg q28 days |
September 2022 (preoperative) | 236.6 | 9.3 | 20.6 | CC: 2.7 TR: 1.9 AP: 1.7 | CAB 2 mg 3×/week LT4 50 mcg OM T 100 mg q28 days |
September 2022 (postoperative) | 133.2 | – | – | – | CAB 1 mg 2×/week LT4 50 mcg OM T 100 mg q28 days |
October 2022 | 99.9 | 12.5 | – | Intrasellar component: CC: 0.7 TR: 0.9 AP: 1.3 Suprasellar component: CC: 0.9 TR: 2.0 AP: 0.8 | CAB 2 mg 3×/week LT4 100 mcg OM T 100 mg q28 days |